ArticleLung India : official organ of Indian Chest Society2026
Role of serum biomarkers KL-6, SP-D and CCL-18 in assessing interstitial lung disease in systemic sclerosis: A prospective observational study from India.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Figure-text discrepancy and methodological considerations in evaluating KL-6, SP-D, and CCL-18 as biomarkers of SSc-ILD in Indian patients.Lung India : official organ of Indian Chest Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic sclerosis (SSc) is a connective tissue disorder characterized by fibrosis of the skin and internal organs, with interstitial lung disease (ILD) affecting over 50% of patients. Early detection and monitoring of SSc-ILD are essential for timely intervention.
objectivesTo evaluate the utility of serum biomarkers Krebs von den Lungen 6 (KL-6), C-C motif chemokine ligand 18 (CCL-18) and surfactant protein D (SP-D) in assessing ILD in Indian patients with SSc.
methodsIn this prospective observational study, 76 patients with SSc were evaluated for ILD using high-resolution computed tomography (HRCT), pulmonary function tests (PFTs) and serum biomarker levels. Correlations between biomarker levels and clinical, radiological and functional parameters were assessed.
resultsSerum KL-6 levels showed a significant negative correlation with forced vital capacity (FVC) ( r = -0.58, P = 0.01) and were significantly elevated in patients with progressive ILD ( P < 0.0001). SP-D levels correlated significantly with HRCT scores ( r = 0.42, P = 0.04), diffusing capacity of carbon monoxide ( r = -0.528, P = 0.017) and modified Rodnan Skin Score (mRSS) ( r = 0.42, P = 0.02). CCL-18 levels demonstrated a strong positive correlation with mRSS ( r = 0.72, P = 0.016). KL-6 and CCL-18 levels were higher in patients with diffuse cutaneous SSc. SP-D levels were significantly elevated in SSc patients with ILD compared to those without ( P = 0.04).
conclusionKL-6 and SP-D are promising tools for monitoring disease progression and guiding treatment in SSc-ILD, with KL-6 reflecting early alveolar inflammation and SP-D indicating the extent of alveolar injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.